In liver cancer, particularly HCC, PD-1/PD-L1 inhibitors have shown promise in enhancing antitumor immune responses. Liver cancer cells can express PD-L1, which binds to PD-1 on T cells, leading to the inhibition of T cell activation and allowing tumor cells to escape immune detection and destruction. Blocking the interaction between PD-1 and PD-L1 with ICIs reactivates T cells, enabling them to recognize and kill cancer cells. The liver unique immune environment, rich in immunosuppressive cells, creates a challenge for effective immune responses. PD-1/PD-L1 inhibitors help to overcome this immunosuppressive microenvironment. High PD-L1 expression in liver cancer is associated with poor prognosis, making it a potential prognostic marker. The PD-L1 | liver cancer biomarker-cancer type concept pair appears to be growing at a moderate pace (the average fold increase being 2-fold) with an upward trend (Figure and Supporting Information S1).